Graftys announced the renewal of its multi-year supply agreement with Arthrex for advanced synthetic bone graft materials.
Aurelien Valet, Graftys’ Chief Executive Officer, said, “We are proud that Arthrex has renewed its trust in Graftys through this long-term agreement which will provide multiple new business opportunities using state-of-the-art orthobiologic technology. Arthrex is one of the most successful and innovative companies in the orthopedic industry and we look forward to continuing our collaboration with them to address unmet clinical needs in sports medicine, orthopedic reconstruction and trauma, on a global basis.”
David Shepard, Senior Director, Orthobiologics and Vet Systems at Arthrex, added, “We are pleased to renew our relationship with Graftys in support of our mission to help surgeons treat their patients better.”
Graftys is committed to the development and manufacturing of synthetic bone biomaterials. Its products are registered in more than 25 countries worldwide, including Europe, the U.S. and South America. Last month, the company completed an investment round of €2 million (~US $2.03 million) with its existing shareholders. Graftys is developing new generations of products for market launch in 2023 and 2024.
Graftys announced the renewal of its multi-year supply agreement with Arthrex for advanced synthetic bone graft materials.
Aurelien Valet, Graftys’ Chief Executive Officer, said, “We are proud that Arthrex has renewed its trust in Graftys through this long-term agreement which will provide multiple new business opportunities using...
Graftys announced the renewal of its multi-year supply agreement with Arthrex for advanced synthetic bone graft materials.
Aurelien Valet, Graftys’ Chief Executive Officer, said, “We are proud that Arthrex has renewed its trust in Graftys through this long-term agreement which will provide multiple new business opportunities using state-of-the-art orthobiologic technology. Arthrex is one of the most successful and innovative companies in the orthopedic industry and we look forward to continuing our collaboration with them to address unmet clinical needs in sports medicine, orthopedic reconstruction and trauma, on a global basis.”
David Shepard, Senior Director, Orthobiologics and Vet Systems at Arthrex, added, “We are pleased to renew our relationship with Graftys in support of our mission to help surgeons treat their patients better.”
Graftys is committed to the development and manufacturing of synthetic bone biomaterials. Its products are registered in more than 25 countries worldwide, including Europe, the U.S. and South America. Last month, the company completed an investment round of €2 million (~US $2.03 million) with its existing shareholders. Graftys is developing new generations of products for market launch in 2023 and 2024.
Copy to clipboard 
